For most of 2024–2025, Novo Nordisk looked like it was falling behind Eli Lilly in the weight-loss arms race. Tirzepatide was out-performing semaglutide head-to-head, and retatrutide was pulling in Phase 2 numbers nobody had seen before. Novo's answer was CagriSema — a fixed-dose combination of cagrilintide (a long-acting amylin analogue) and semaglutide — delivered in a single weekly injection. The Phase 3 REDEFINE-1 trial reported out, and the headline is a 22.7% body weight reduction at 68 weeks. Here's what that number means in context, and what it doesn't.
Key Takeaways
- 22.7% body weight loss at 68 weeks in REDEFINE-1 — the primary endpoint was met, but the 25%+ Novo had telegraphed to investors was not.
- Two peptides in one injection. Semaglutide 2.4 mg (GLP-1 agonist) + cagrilintide 2.4 mg (amylin analogue) — hits two distinct appetite-regulation pathways.
- 60% of participants lost ≥20%, and 23% lost ≥30% — a meaningful uplift in the "high-responder" tail.
- Did not demonstrate non-inferiority to tirzepatide 15 mg in head-to-head comparison at 84 weeks — the first major GLP-1-class trial to miss its primary comparator endpoint.
- Only 57% of patients reached the top dose. GI tolerability and slow titration remain the gating factor.
- FDA filed for approval. First combination GLP-1 + amylin product — US decision expected Q4 2026.
Why Cagrilintide Matters
Semaglutide is a GLP-1 receptor agonist. It reduces appetite via a slow, central-nervous-system satiety signal and slows gastric emptying. The upside: durable weight loss. The downside: a defined ceiling of effect that most patients plateau at.
Cagrilintide is a long-acting amylin analogue. Amylin is a hormone co-secreted with insulin from pancreatic beta cells, and it acts on hindbrain receptors to produce satiety through a mechanistically distinct pathway. In short, cagrilintide and semaglutide tell your brain "you're full" via two different routes. In theory, the signals should stack. In REDEFINE-1, they largely did.
REDEFINE-1 Trial Design
REDEFINE-1 enrolled adults with obesity (BMI ≥30, or ≥27 with weight-related comorbidities) and without diabetes. Participants were randomised to:
- CagriSema 2.4/2.4 mg weekly
- Cagrilintide 2.4 mg weekly (monotherapy arm)
- Semaglutide 2.4 mg weekly (Wegovy arm)
- Placebo
Treatment was delivered subcutaneously once weekly for 68 weeks following a ~16-week dose escalation. Primary endpoint: percent change in body weight.
Headline Numbers
At 68 weeks:
- CagriSema: –22.7%
- Semaglutide 2.4 mg (monotherapy): –16.1%
- Cagrilintide 2.4 mg (monotherapy): –11.8%
- Placebo: –2.3%
Responder analysis:
- ≥10% weight loss: ~80% of CagriSema participants
- ≥20% weight loss: ~60%
- ≥30% weight loss: ~23%
Adding cagrilintide to semaglutide delivered approximately 6.6 additional percentage points of weight loss over semaglutide alone — not nothing, but not the dramatic uplift Novo had primed investors to expect.
The Missed 25% Target
Novo had publicly signalled a 25%+ expectation. 22.7% is a strong number in absolute terms, but it fell short of that bar and triggered a sharp stock reaction when first reported in December 2024. In February 2026, follow-up analysis at 84 weeks showed CagriSema at 2.4/2.4 mg did not demonstrate non-inferiority to tirzepatide 15 mg on weight loss — a significant data point because it means Novo's flagship obesity program is now objectively trailing Lilly's dual-agonist.
The Titration Problem
Only 57% of REDEFINE-1 participants reached the full 2.4/2.4 mg dose. GI side effects — nausea, vomiting, diarrhea, constipation — were the primary reason for dropouts and dose reductions. This is the same ceiling that limits semaglutide and tirzepatide in practice: pharmacology that works in the dose-escalated group doesn't necessarily translate to real-world patients who can't tolerate the top dose.
Novo has signalled that future CagriSema formulations may include slower, more individualised titration schedules, or dose combinations with lower cagrilintide ratios for patients who tolerate semaglutide well but struggle to escalate cagrilintide.
How CagriSema Compares
Approximate weight-loss ranges in Phase 3 obesity data, matched follow-up windows:
- Retatrutide 12 mg (triple agonist, 104 weeks): ~28–30%
- CagriSema (68–84 weeks): ~22.7%
- Tirzepatide 15 mg (72 weeks): ~22%
- Semaglutide 2.4 mg (68 weeks): ~15–16%
- Orforglipron 36 mg (oral, 72 weeks): ~12.4%
CagriSema sits roughly level with tirzepatide — meaningful uplift over semaglutide alone, but not the ceiling-breaking move retatrutide represents. The mechanistic story is different (amylin + GLP-1 vs. triple incretin agonism), and that difference may matter clinically for patients who don't tolerate incretin receptors well.
The Regulatory Path
Novo Nordisk filed for FDA approval of CagriSema in late 2025 for weight management. Decision timing: Q4 2026. If approved, CagriSema becomes the first fixed-dose combination of a GLP-1 agonist and an amylin analogue — a new product category.
The approval case is strong on absolute numbers (22.7% is clinically meaningful and well above semaglutide alone), but complicated by the tirzepatide comparator miss. The FDA will likely approve based on placebo and semaglutide-arm superiority rather than on head-to-head against tirzepatide.
What This Means Strategically
Three takeaways for the broader peptide landscape:
- Multi-mechanism beats single mechanism. Every drug outperforming semaglutide (tirzepatide, retatrutide, CagriSema) does so by stacking distinct pathways. The era of single-receptor obesity drugs may be effectively over.
- Novo is behind, but not out. Semaglutide is still the largest-selling GLP-1. CagriSema's missed 25% target is a disappointment, not a failure. The real risk is sitting still while Lilly rolls out tirzepatide-cardiovascular, retatrutide-obesity, retatrutide-sleep apnea, and orforglipron-oral in quick succession.
- Patient-level pathway matters. For patients who plateau on semaglutide, or who can't escalate GIP-containing dual agonists like tirzepatide, CagriSema's amylin-plus-GLP-1 combination may unlock continued progress where incretin-only options stall.
Frequently Asked Questions
What is CagriSema?
CagriSema is a once-weekly injectable combination of two peptides: cagrilintide (a long-acting amylin analogue) and semaglutide (a GLP-1 receptor agonist). It is Novo Nordisk's next-generation obesity drug and the first fixed-dose combination of a GLP-1 and amylin analogue to reach Phase 3 and FDA filing.
How much weight did patients lose on CagriSema?
In REDEFINE-1, participants on CagriSema 2.4/2.4 mg lost an average of 22.7% of body weight at 68 weeks. 60% lost ≥20% and 23% lost ≥30%. This compares to 16.1% for semaglutide alone and 11.8% for cagrilintide alone.
Is CagriSema FDA-approved?
Not yet. Novo Nordisk submitted the FDA application in late 2025. The approval decision is expected in Q4 2026. If approved, it would be the first GLP-1 + amylin combination therapy for weight management.
Is CagriSema better than tirzepatide?
Based on current data: no. In a head-to-head comparison reported in February 2026, CagriSema 2.4/2.4 mg did not demonstrate non-inferiority to tirzepatide 15 mg at 84 weeks. Both drugs land around 22% weight loss, but tirzepatide retains a modest edge in matched comparisons.
Why did CagriSema miss its 25% target?
The primary issue was titration tolerability. Only 57% of REDEFINE-1 participants reached the full 2.4/2.4 mg dose. GI side effects — nausea, vomiting, diarrhea — forced many patients to stay at lower doses, which capped the achievable weight loss. The pharmacology at full dose works; getting patients to full dose is harder than the Phase 2 data suggested.
What are the side effects of CagriSema?
The side effect profile is similar to other GLP-1 class drugs: nausea, vomiting, diarrhea, and constipation dominate. Most events are mild-to-moderate and dose-escalation-related. Novo has not reported new pancreatic or thyroid safety signals specific to the combination.
How does CagriSema compare to retatrutide?
Retatrutide (a triple agonist of GLP-1, GIP, and glucagon) produces greater weight loss — approximately 28–30% at 104 weeks on the top dose, compared to CagriSema's 22.7% at 68 weeks. Retatrutide reaches further; CagriSema uses a different mechanistic combination (amylin + GLP-1) that may suit different patient profiles.
When will CagriSema be available?
If the FDA approves in Q4 2026 on standard timelines, commercial availability could begin in early-to-mid 2027. Novo Nordisk has signalled it is preparing manufacturing capacity ahead of approval to avoid the shortage situation that affected Ozempic and Wegovy in 2023–2024.
Primary sources:
- HCPLive — CagriSema Achieves 22.7% Weight Loss in Phase 3 REDEFINE-1 Trial
- Applied Clinical Trials — REDEFINE-1 Trial Finds Cagrilintide–Semaglutide Combo Delivers Over 20% Weight Loss
- Pharm Exec — Novo Nordisk's CagriSema Falls Short of 25% Weight Loss Target
- Novo Nordisk — Files for FDA Approval of CagriSema
- ClinicalTrials.gov — REDEFINE 2 (T2D) Study Record
Research disclaimer: This article summarises published Phase 3 clinical trial data and regulatory timelines for educational purposes. CagriSema is an investigational product at the time of writing. No information here constitutes medical advice. Always consult a licensed healthcare provider.
